Volume 21, Number 3—March 2015
Research
Multidrug-Resistant Tuberculosis in Europe, 2010–2011
Table 2
Drug resistance profiles for first-line and second-line drugs used for treatment of multidrug-resistant tuberculosis in TBNET study in Europe, 2010–2011*
Drug† |
Incidence of TB in region |
All MDR TB patients,
n = 380 |
||||||||
Low, n = 103† |
Intermediate n = 86‡ |
High n = 191§ |
||||||||
Tested |
Resistant |
Tested |
Resistant |
Tested |
Resistant |
Tested |
Resistant |
|||
First-line | ||||||||||
Pyrazinamide | 97 (94.2) | 52 (53.6) | 70 (81.4) | 49 (71.0) | 10 (5.2) | 4 (40.0) | 177 (45.0) | 105 (59.7) | ||
Ethambutol | 99 (96.1) | 50 (50.5) | 85 (98.9) | 55 (64.7) | 187 (97.9) | 115 (61.5) | 371 (97.6) | 220 (59.3) | ||
Streptomycin |
93 (90.3) |
78 (83.9) |
85 (98.9) |
82 (96.5) |
187 (97.9) |
171 (91.4) |
365 (96.1) |
331 (90.7) |
||
≥1 non–first line |
101 (97.1) |
66 (65.4) |
86 (100) |
64 (74.4) |
173 (86.4) |
64 (37.0) |
360 (94.7) |
194 (51.1) |
||
Class II | ||||||||||
Amikacin | 95 (92.2) | 17 (17.9) | 85 (98.8) | 25 (29.4) | 1 (0.5) | 0 | 181 (47.6) | 42 (23.2) | ||
Kanamycin | 39 (37.9) | 8 (20.5) | 79 (91.9) | 37 (46.8) | 170 (89.0) | 23 (13.5) | 288 (75.8) | 68 (23.6) | ||
Capreomycin | 88 (85.4) | 15 (17.0) | 84 (97.7) | 26 (31.0) | 94 (49.2) | 4 (4.3) | 266 (71.1) | 45 (16.9) | ||
≥1 second-line inj. |
100 (97.1) |
24 (24.0) |
86 (100) |
42 (48.8) |
170 (89.0) |
27 (15.9) |
356 (93.7) |
93 (26.1) |
||
Class III | ||||||||||
Ofloxacin | 69 (67.0) | 16 (23.2) | 86 (100) | 26 (30.2) | 169 (88.5) | 14 (8.3) | 324 (85.3) | 56 (17.3) | ||
Levofloxacin | 16 (15.5) | 1 (6.2) | 7 (8.1) | 1 (14.3) | 10 (5.2) | 2 (20.0) | 32 (8.4) | 4 (12.5) | ||
Moxiflocacin | 61 (59.2) | 14 (23.0) | 12 (14.0) | 3 (25.0) | 0 | 73 (19.2) | 17 (23.3) | |||
≥1 fluoroquinolone |
96 (96.2) |
21 (21.9) |
86 (100) |
26 (30.2) |
170 (89.0) |
15 (8.8) |
352 (92.6) |
62 (17.6) |
||
Class IV | ||||||||||
ETO/PTO | 98 (95.1) | 47 (48.0) | 86 (100) | 36 (41.9) | 170 (89.0) | 36 (21.2) | 354 (93.2) | 119 (31.3) | ||
PAS | 54 (52.4) | 10 (18.5) | 68 (79.1) | 10 (14.7) | 175 (91.6) | 2 (1.1) | 295 (77.6) | 22 (7.5) | ||
DCS/TRD |
53 (51.5) |
6 (11.3) |
69 (80.2) |
13 (18.8) |
100 (52.4) |
5 (5.0) |
220 (57.9) |
23 (10.6) |
||
Class V | ||||||||||
Linezolid | 62 (60.2) | 2 (3.2) | 6 (7.0) | 0 | 1 (0.5) | 0 | 69 (18.2) | 2 (2.9) | ||
Imipenem | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Meropenem | 1 (1.0) | 1 (100) | 0 | 0 | 0 | 0 | 1 (0.3) | 1 (100) | ||
AMX/CLV | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Clarithromycin | 17 (16.5) | 3 (17.7) | 0 | 0 | 0 | 0 | 17 (4.5) | 3 (17.6) |
*Values are no. (%) samples. Unweighted analysis was used. TB, tuberculosis; MDR TB, multidrug-resistant tuberculosis; inj, injectable; ETO/PTO, ethionamide/prothionamide; PAS, para-aminosalicylic acid; DCS/TRD, cycloserine/terizidone; AMX/CLV, amoxicillin/clavulanic acid.
†Austria, Belgium, Czech Republic, Denmark, Germany, Great Britain, Ireland, Netherlands, Italy, and Spain.
‡Belarus, Estonia, Latvia, and Portugal.
§Moldova and Romania.
1Additional contributors from TBNET are listed at the end of this article.